Last reviewed · How we verify
NCT06255665
A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors
Phase 1 trial testing JNJ-79032421 in Advanced Stage Solid Tumors in 35 participants. Completed in 23 June 2025.
23 June 2025
Quick facts
| Lead sponsor | Janssen Research & Development, LLC |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 35 |
| Start date | 9 February 2024 |
| Primary completion | 23 June 2025 |
| Estimated completion | 23 June 2025 |
| Sites | 3 locations across Spain |
Drugs / interventions tested
- JNJ-79032421 — full drug profile →
- JNJ-79032421 — full drug profile →
Conditions studied
- Advanced Stage Solid Tumors — all drugs for Advanced Stage Solid Tumors →
Sponsor
Janssen Research & Development, LLC — full company profile →
Who can join
18 and older, any sex, with Advanced Stage Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-79032421 and to determine the safety and tolerability of JNJ-79032421 at the RP2D(s).
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Bispecific Antibodies in Solid Tumors: Advances and Challenges.
Shan KS, Musleh Ud Din S, Dalal S, Gonzalez T, et al · · 2025 · cited 12× · PMID 40565299 · DOI 10.3390/ijms26125838 -
Current landscape of T-cell engagers in early-phase clinical development in solid cancers.
Spinazzola A, Iannantuono GM, Gulley JL, Giudice E, et al · · 2025 · cited 3× · PMID 41122165 · DOI 10.3389/fimmu.2025.1665838 -
Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations.
Silvestri R, Colucci E, Piccardi M, Landi S, et al · · 2025 · cited 2× · PMID 41335396 · DOI 10.1186/s43556-025-00379-z -
Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager.
Kosti P, Abram-Saliba J, Pericou-Troquier L, Pavelot S, et al · · 2025 · cited 1× · PMID 40081946 · DOI 10.1136/jitc-2024-010063 -
Revolutionizing cancer immunotherapy: T cell engagers beyond hematologic malignancies toward solid tumors.
Wu X, Li P, Li T, Fan Q, et al · · 2026 · PMID 42245672 · DOI 10.3389/fimmu.2026.1774471 -
Mesothelin biology and the evolving landscape of targeted immunotherapy.
Boisgard R, Chames P, Kerfelec B. · · 2026 · PMID 41994562 · DOI 10.1016/j.omton.2026.201148
Verify or expand the search:
- PubMed search for NCT06255665
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Janssen Research & Development, LLC trials
Trials by the same sponsor.
- NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
- NCT07309445 — A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC · recruiting
- NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
- NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
- NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06255665 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Janssen Research & Development, LLC
- Last refreshed: 20 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06255665.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing